These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23761048)

  • 1. Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling.
    Ding X; He M; Kulkarni R; Patel N; Zhang X
    J Pharm Sci; 2013 Aug; 102(8):2859-74. PubMed ID: 23761048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.
    Wong CJ; Witcher J; Mallinckrodt C; Dean RA; Anton RF; Chen Y; Fijal BA; Ouyang H; Dharia S; Sundseth SS; Schuh KJ; Kinon BJ
    Alcohol Clin Exp Res; 2014 Feb; 38(2):511-20. PubMed ID: 24010675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Food, gastrointestinal pH, and models of oral drug absorption.
    Abuhelwa AY; Williams DB; Upton RN; Foster DJ
    Eur J Pharm Biopharm; 2017 Mar; 112():234-248. PubMed ID: 27914234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products.
    Sugihara M; Takeuchi S; Sugita M; Higaki K; Kataoka M; Yamashita S
    Mol Pharm; 2015 Dec; 12(12):4405-13. PubMed ID: 26568266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
    Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
    Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms.
    Thelen K; Coboeken K; Willmann S; Dressman JB; Lippert J
    J Pharm Sci; 2012 Mar; 101(3):1267-80. PubMed ID: 22125236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.
    Ding X; Gueorguieva I; Wesley JA; Burns LJ; Coutant CA
    AAPS J; 2015 Nov; 17(6):1395-406. PubMed ID: 26126932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances and challenges in PBPK modeling--Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base.
    Berlin M; Ruff A; Kesisoglou F; Xu W; Wang MH; Dressman JB
    Eur J Pharm Biopharm; 2015 Jun; 93():267-80. PubMed ID: 25872159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species.
    Daublain P; Feng KI; Altman MD; Martin I; Mukherjee S; Nofsinger R; Northrup AB; Tschirret-Guth R; Cartwright M; McGregor C
    Mol Pharm; 2017 May; 14(5):1634-1645. PubMed ID: 28329443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canine gastrointestinal physiology: Breeds variations that can influence drug absorption.
    Oswald H; Sharkey M; Pade D; Martinez MN
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):192-203. PubMed ID: 26409436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract.
    Fernandez-Teruel C; Mangas-Sanjuan V; Gonzalez-Alvarez I; Ruiz-Garcia A; Casabó VG; Bermejo M
    Xenobiotica; 2013 Sep; 43(9):745-54. PubMed ID: 23294363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling.
    Wong H; Theil FP; Cui Y; Marsters JC; Khojasteh SC; Vernillet L; La H; Song X; Wang H; Morinello EJ; Deng Y; Hop CE
    Drug Metab Dispos; 2010 Jul; 38(7):1029-38. PubMed ID: 20406853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
    Paixão P; Gouveia LF; Morais JA
    Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.